cvp-nasvac

CVP-NASVAC is a therapeutic vaccine candidate designed for the treatment of chronic hepatitis B virus (HBV) infection. Developed through a collaboration between the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba and researchers in Japan (supported by AMED), the vaccine is a recombinant protein formulation containing two key HBV antigens: the hepatitis B surface antigen (HBsAg) and the hepatitis B core antigen (HBcAg). Unlike traditional prophylactic vaccines, CVP-NASVAC is intended to break immune tolerance in individuals already infected with HBV by stimulating a robust T-cell mediated immune response. The vaccine is primarily administered via the intranasal route, which is thought to induce mucosal immunity and bypass the need for needles, although it has also been evaluated in combination with other administration methods. Clinical trials, including Phase 2 studies in Japan, have focused on its efficacy in chronic carriers and liver transplant patients, monitoring endpoints such as HBsAg loss and virologic/immunologic responses.

Brand names

NASVACHeberNasvac

Other names

NASVAC vaccineHBsAg-HBcAg therapeutic vaccine